The decision was based on a study conducted by the National Institute of Allergy and Infectious Disease that tested the drug in more than 1,000 patients and found it caused a 31 percent faster recovery time compared to a placebo, STAT reported.
The emergency use authorization allows physicians to treat COVID-19 patients with the drug only during the time COVID-19 is declared a public health emergency in the U.S.
Earlier this week, Gilead released results from its own clinical trial of remdesivir involving 397 patients with severe COVID-19 infection that showed at least 50 percent of patients treated with a five-day dosage of remdesivir improved.
Remdesivir is an intravenous drug that works by targeting the system coronaviruses use to replicate themselves. It was tested to treat Ebola but hasn’t been officially approved in any country.
More articles on pharmacy:
Clinical trials for COVID-19 drugs & when to expect results
The race to develop a COVID-19 vaccine: 4 updates
Walgreens lowers prices on hundreds of prescription drugs
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.